Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 8410287.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical oncology needs flexible techniques for routine monitoring of treatment response. We therefore compared planar 18F-fluorodeoxyglucose (FDG) with a conventional gamma-camera and a special collimator to 67Ga scintigraphy in 26 patients with malignant lymphoma during chemotherapy. The scintigraphic appearance of involved sites was essentially the same with both tracers: in patients eventually achieving complete remission, tracer distribution had normalized after two courses; high uptake reflected treatment failure; faint uptake was associated with variable outcome. For (re)staging, 67Ga may be preferable (higher contrast). To document the initial response, we performed FDG scintigraphy during the first course (n = 11). Effective treatment sharply reduced metabolic tumor activity within days and prior to volume response, whereas abnormal uptake persisted in treatment failure. Planar FDG scintigraphy may be a tool to assess the potentially prognostic initial response rate, preventing over-treatment and allowing a timely switch to more aggressive therapy.
Medical subject headings
- Deoxyglucose
- Hodgkin Disease
- Lymphoma, Non-Hodgkin